The US Court of Appeal for the seventh circuit rejects "Patent Thicket" allegation against a pharmaceutical company, on the claim of prevention of market entry (AbbVie)

Seventh Circuit’s Rejection of Insurers’ Monopolization Case is Not the Final Word on “Patent Thicket” Litigation* The theory that patent holders can be held liable under the antitrust laws for blocking competition with a thicket of patents may be down—but it is not out. Although the “patent thicket” theory was unsuccessful in Mayor and City Council of Baltimore, et al. v. AbbVie Inc., et al., this recent decision of the U.S. Court of Appeals for the Seventh Circuit hints at ways that theory could support a viable monopolization claim. The Seventh Circuit panel affirmed a district court’s decision to dismiss claims brought by insurers against drugmaker AbbVie for monopolizing the market for the Humira arthritis drug by

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Constantine Cannon (New York)

Quotation

Sarah Bayer, The US Court of Appeal for the seventh circuit rejects "Patent Thicket" allegation against a pharmaceutical company, on the claim of prevention of market entry (AbbVie), 1 August 2022, e-Competitions August 2022, Art. N° 108665

Visites 17

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues